Published online Jul 28, 2024. doi: 10.4329/wjr.v16.i7.265
Revised: June 8, 2024
Accepted: July 2, 2024
Published online: July 28, 2024
Processing time: 76 Days and 16.9 Hours
Bone is one of the common sites of metastasis from prostate carcinoma. Bone scintigraphy (BS) is one of the most sensitive imaging modalities currently used for bone metastatic work-up. Skeletal metastasis in prostate carcinoma commonly involves pelvic bones but rarely involves extrapelvic-extraspinal sites.
To retrospectively analyze the BS data to determine the pattern of skeletal metastases in the prostate carcinoma.
This retrospective observational study involves patients with biopsy-proven prostate carcinoma referred for BS for staging assessment. Patients with abnormal BS were evaluated for the pattern of skeletal involvement and data were pre
A total of 150 patients with biopsy-proven prostate cancer who were referred for staging were included in the study. Thirteen of 150 patients (8.67%) had no abnormal uptake on planar images, ruling out metastatic disease. Twenty-four patients (16%) had heterogeneous uptake in the spine with distribution characteristic of degenerative disease and no scan pattern of metastatic disease. Thirty patients (20%) had multifocal uptake involving both pelvic and extra pelvic bones on planar images typical for skeletal metastasis and were considered metastatic. Eighty-three out of 150 patients (55.3%) had increased tracer uptake, which was indeterminate, thus, single photon emission computed tomography-computed tomography (SPECT-CT) was acquired, which showed 51 with metastatic disease, 31 benign lesions, and one indeterminate finding. Seven of 150 patients had exclusive pelvic bone uptake, which was found to be metastatic in 4/7 patients in SPECT-CT. Fifty six out of 150 patients showed exclusive extrapelvic tracer uptake, of which only 3 had vertebral metastatic disease. None of the patients with increased uptake exclusively in the extrapelvic-extraspinal location was metastatic.
The incidence of exclusive extrapelvic skeletal metastatic disease in prostate carcinoma is 2% (excluding one patient with indeterminate findings). Further, none of the patients in the current study had exclusive extrapelvic-extraspinal metastasis. Thus, exclusive extrapelvic-extraspinal focal abnormality on planar BS carries a very low probability of metastatic disease and hence, further imaging or SPECT-CT can be safely avoided in such cases.
Core Tip: The current study analyzed bone scintigraphy (BS) data from 150 patients with biopsy-proven prostate carcinoma to determine skeletal metastasis patterns. The most common site of skeletal metastasis was pelvis. The incidence of exclusive extrapelvic skeletal metastatic disease was 2%, excluding one indeterminate case. Additionally, no patients in the study had exclusive extrapelvic-extraspinal metastasis. Therefore, exclusive extrapelvic-extraspinal focal abnormalities on planar BS have a very low likelihood of being metastatic, making further imaging or single photon emission computed tomography-computed tomography often unnecessary.